ImmunityBio, Inc. (IBRX): Submission of Matters to a Vote of Security Holders
ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ibrx-20260609 FALSE 0001326110 0001326110 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
How this was made
The 30-second read
Why it matters
Re-election of directors and ratification of the independent auditor are standard governance items; absent any disclosed dissent, it is unlikely to change near-term valuation drivers.
Market read
Traders may treat this as a routine proxy tabulation with minimal trading signal unless paired with other contemporaneous catalysts.
What to watch
Broker non-votes and withheld votes can matter for proxy narratives, but the 8-K does not indicate a contested outcome or strategic change.
Background
The SEC 8-K (Item 5.07) summarizes matters submitted to a vote of stockholders at ImmunityBio’s 2026 Annual Meeting on June 9, 2026.
Ticker impact
ImmunityBio’s 8-K reports the June 9, 2026 annual meeting vote results, including re-election of nine directors and ratification of Deloitte & Touche.
Low near-term impact; any reaction is likely limited to sentiment around governance/proxy outcomes rather than operations.
The filing is a routine post-meeting tabulation (Item 5.07) with no new financial guidance, clinical/regulatory decision, or transaction disclosed.
Market effects
No direct read-across to biotech sector fundamentals; governance-only disclosure.
None.
None.
Counterpoint
If the vote outcomes were contentious, traders might watch for follow-on proxy/activism headlines; however, this filing provides no such context beyond vote counts.
Key entities
- issuerImmunityBio, Inc.
Nasdaq-listed company whose annual meeting vote results are reported in the 8-K.
- auditorDeloitte & Touche LLP
Independent registered public accounting firm appointment ratified for fiscal year ending Dec. 31, 2026.
